Alpha 2.0
Login Register
» Authors » Katia Manova-Todorova

Katia Manova-Todorova

Explore the profile of Katia Manova-Todorova including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 56
Citations 5775
Followers 0
Related Specialties
Oncology
Science
Cell Biology
Top 10 Co-Authors
Afsar Barlas
Yevgeniy Romin
Sho Fujisawa
Ning Fan
Elisa de Stanchina
Joan Massague
Mesruh Turkekul
Emil Lou
Malcolm A S Moore
Dmitry Yarilin
Published In
Proc Natl Acad Sci U S A
Nat Commun
Clin Cancer Res
Methods Mol Biol
Cell
Affiliations
Soon will be listed here.
Recent Articles
1.
Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations that Overcome it's Feedback Inhibition of RAC1 and Migration
Gadal S, Boyer J, Roy S, Outmezguine N, Sharma M, Li H, et al.
Cancer Res . 2025 Feb; PMID: 39992718
BRAFV600E mutations occur in 46% of melanomas and drive high levels of ERK activity and ERK-dependent proliferation. However, BRAFV600E is insufficient to drive melanoma in genetically engineered mouse models, and...
2.
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer
Elkrief A, Montesion M, Sivakumar S, Hale C, Bowman A, Bektas A, et al.
J Clin Oncol . 2024 Jul; 42(28):3339-3349. PMID: 39038258
PURPOSEThe impact of the intratumoral microbiome on immune checkpoint inhibitor (ICI) efficacy in patients with non-small-cell lung cancer (NSCLC) is unknown. Preclinically, intratumoral Escherichia is associated with a proinflammatory tumor...
3.
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A . 2024 Jul; 121(28):e2322203121. PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
4.
FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
Tai Y, Chow A, Han S, Coker C, Ma W, Gu Y, et al.
EMBO Mol Med . 2024 Jul; 16(8):1957-1980. PMID: 38956205
Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfully...
5.
Tumorigenesis driven by the BRAF oncoprotein requires secondary mutations that overcome its feedback inhibition of migration and invasion
Gadal S, Boyer J, Roy S, Outmezguine N, Sharma M, Li H, et al.
bioRxiv . 2024 Apr; PMID: 38659913
mutation occurs in 46% of melanomas and drives high levels of ERK activity and ERK-dependent proliferation. However, is insufficient to drive melanoma in GEMM models, and 82% of human benign...
6.
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv . 2024 Apr; PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
7.
Membrane-derived particles shed by PSMA-positive cells function as pro-angiogenic stimuli in tumors
Machado C, Skubal M, Haedicke K, Silva F, Stater E, Silva T, et al.
J Control Release . 2023 Oct; 364:312-325. PMID: 37884210
Cell membrane-derived particles (Mp) are rounded membrane-enclosed particles that are shed from tumor cells. Mp are formed from tumor membranes and are capable of tumor targeting and immunotherapeutic agents because...
8.
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Gleason C, Dickson M, Klein Dooley M, Antonescu C, Gularte-Merida R, Benitez M, et al.
Clin Cancer Res . 2023 Sep; 30(4):703-718. PMID: 37695642
Purpose: We conducted research on CDK4/6 inhibitors (CDK4/6i) simultaneously in the preclinical and clinical spaces to gain a deeper understanding of how senescence influences tumor growth in humans. Patients And...
9.
Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation
Rodina A, Xu C, Digwal C, Joshi S, Patel Y, Santhaseela A, et al.
Nat Commun . 2023 Jun; 14(1):3742. PMID: 37353488
Systems-level assessments of protein-protein interaction (PPI) network dysfunctions are currently out-of-reach because approaches enabling proteome-wide identification, analysis, and modulation of context-specific PPI changes in native (unengineered) cells and tissues are...
10.
Multiplex Spatial Protein Detection by Combining Immunofluorescence with Immunohistochemistry
Kang W, Santella A, Rosiek E, Pulina M, Chan E, Fan N, et al.
Methods Mol Biol . 2022 Dec; 2593:233-244. PMID: 36513935
Technologies for staining and imaging multiple antigens in single tissue sections are developing rapidly due to their potential to uncover spatial relationships between proteins with cellular resolution. Detections are performed...